全文获取类型
收费全文 | 10405篇 |
免费 | 624篇 |
国内免费 | 82篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 256篇 |
妇产科学 | 264篇 |
基础医学 | 1518篇 |
口腔科学 | 182篇 |
临床医学 | 794篇 |
内科学 | 2672篇 |
皮肤病学 | 122篇 |
神经病学 | 1520篇 |
特种医学 | 413篇 |
外科学 | 917篇 |
综合类 | 16篇 |
一般理论 | 3篇 |
预防医学 | 467篇 |
眼科学 | 130篇 |
药学 | 788篇 |
中国医学 | 10篇 |
肿瘤学 | 967篇 |
出版年
2024年 | 26篇 |
2023年 | 171篇 |
2022年 | 291篇 |
2021年 | 495篇 |
2020年 | 272篇 |
2019年 | 390篇 |
2018年 | 430篇 |
2017年 | 317篇 |
2016年 | 372篇 |
2015年 | 393篇 |
2014年 | 557篇 |
2013年 | 650篇 |
2012年 | 840篇 |
2011年 | 872篇 |
2010年 | 501篇 |
2009年 | 460篇 |
2008年 | 657篇 |
2007年 | 593篇 |
2006年 | 580篇 |
2005年 | 512篇 |
2004年 | 376篇 |
2003年 | 321篇 |
2002年 | 291篇 |
2001年 | 56篇 |
2000年 | 49篇 |
1999年 | 64篇 |
1998年 | 49篇 |
1997年 | 40篇 |
1996年 | 43篇 |
1995年 | 31篇 |
1994年 | 29篇 |
1993年 | 19篇 |
1992年 | 26篇 |
1991年 | 36篇 |
1990年 | 36篇 |
1989年 | 34篇 |
1988年 | 35篇 |
1987年 | 38篇 |
1986年 | 29篇 |
1985年 | 15篇 |
1984年 | 12篇 |
1983年 | 7篇 |
1981年 | 12篇 |
1980年 | 6篇 |
1979年 | 11篇 |
1978年 | 7篇 |
1969年 | 6篇 |
1968年 | 8篇 |
1967年 | 7篇 |
1966年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Sabine Kayser Chiara Sartor Marlise R. Luskin Jonathan Webster Fabio Giglio Nydia Panitz Andrew M. Brunner Matthias Fante Christoph Lutz Daniel Wolff Anthony D. Ho Mark J. Levis Richard F. Schlenk Cristina Papayannidis 《Haematologica》2022,107(9):2064
Acute lymphoblastic leukemia (ALL) can relapse in the extramedullary compartment, with or without medullary involvement. Response to treatment may be individual. We evaluated response to inotuzumab ozogamicin in 31 patients with relapsed/refractory B-ALL with extramedullary disease. Median age was 31 years (range, 19-81). All patients were heavily pretreated, including allogeneic hematopoietic stem cell transplantation (HSCT; n=18). Overall response rate after two cycles of inotuzumab ozogamicin was 84% (complete remission, 55%; partial remission, 29%; resistant disease, 13%; early death, 3%). The median follow-up was 29 months and median overall survival was 12.8 months. One-year and 2-year overall survival rates were 53% (95% CI: 37-76%) and 18% (95% CI: 8-43%), respectively. Age had no impact on overall survival when assessed as a continuous variable or dichotomized at 60 years. Twelve patients proceeded to allogeneic HSCT (complete remission, n=6; partial remission, n=3; resistant disease, n=3). Prior to allogeneic HSCT, eight patients received two or fewer cycles and four patients received three or four cycles of inotuzumab ozogamicin. Sinusoidal obstruction syndrome was reported in three patients, including one after transplantation. Allogeneic HSCT, evaluated as a time-dependent variable, had no impact on overall survival. Inotuzumab ozogamicin seems to be effective as a debulking strategy in relapsed/refractory ALL with extramedullary disease. However, inotuzumab ozogamicin followed by allogeneic HSCT seems not to be effective in maintaining long-term disease control. 相似文献
102.
103.
Anna Onnis Emanuele Andreano Chiara Cassioli Francesca Finetti Chiara Della Bella Oskar Staufer Elisa Pantano Valentina Abbiento Giuseppe Marotta Mario Milco DElios Rino Rappuoli Cosima T. Baldari 《The Journal of experimental medicine》2023,220(2)
CTL-mediated killing of virally infected or malignant cells is orchestrated at the immune synapse (IS). We hypothesized that SARS-CoV-2 may target lytic IS assembly to escape elimination. We show that human CD8+ T cells upregulate the expression of ACE2, the Spike receptor, during differentiation to CTLs. CTL preincubation with the Wuhan or Omicron Spike variants inhibits IS assembly and function, as shown by defective synaptic accumulation of TCRs and tyrosine phosphoproteins as well as defective centrosome and lytic granule polarization to the IS, resulting in impaired target cell killing and cytokine production. These defects were reversed by anti-Spike antibodies interfering with ACE2 binding and reproduced by ACE2 engagement by angiotensin II or anti-ACE2 antibodies, but not by the ACE2 product Ang (1-7). IS defects were also observed ex vivo in CTLs from COVID-19 patients. These results highlight a new strategy of immune evasion by SARS-CoV-2 based on the Spike-dependent, ACE2-mediated targeting of the lytic IS to prevent elimination of infected cells. 相似文献
104.
Lucia Maria Sacheli Chiara Verga Laura Zapparoli Silvia Seghezzi Giulia Tomasetig Giuseppe Banfi Eraldo Paulesu 《Human brain mapping》2023,44(2):373
Predicting the unfolding of others'' actions (action prediction) is crucial for successfully navigating the social world and interacting efficiently. Age‐related changes in this domain have remained largely unexplored, especially for predictions regarding simple gestures and independent of contextual information or motor expertise. Here, we evaluated whether healthy aging impacts the neurophysiological processes recruited to anticipate, from the observation of implied‐motion postures, the correct conclusion of simple grasping and pointing actions. A color‐discrimination task served as a control condition to assess the specificity of the age‐related effects. Older adults showed reduced efficiency in performance that was yet not specific to the action prediction task. Nevertheless, fMRI results revealed task‐specific age‐related differences: while both groups showed stronger recruitment of the lateral occipito‐temporal cortex bilaterally during the action prediction than the control task, the younger participants additionally showed a higher bilateral engagement of parietal regions. Importantly, in both groups, the recruitment of visuo‐motor processes in the right posterior parietal cortex was a predictor of good performance. These results support the hypothesis of decreased involvement of sensorimotor processes in cognitive tasks when processing action‐ and body‐related stimuli in healthy aging. These results have implications for social interaction, which requires the fast reading of others'' gestures. 相似文献
105.
Massimo Fabiani Alberto Mateo-Urdiales Chiara Sacco Emmanouil Alexandros Fotakis Maria Cristina Rota Daniele Petrone Marco Bressi Martina Del Manso Andrea Siddu Giorgio Fedele Paola Stefanelli Antonino Bella Flavia Riccardo Anna Teresa Palamara Giovanni Rezza Silvio Brusaferro Patrizio Pezzotti 《Euro surveillance : bulletin européen sur les maladies transmissibles = European communicable disease bulletin》2023,28(8)
Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4–5) mRNA vaccine 7–90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4–6 months earlier indicated no significant additional protection (10%; 95% CI: −44 to 44). A second booster vaccination 6 months after the latest infection may be warranted. 相似文献
106.
Rationale:Whereas metronidazole-induced hepatotoxicity is quite rare in the general population, in individuals carrying a nucleotide excision repair disorder, namely Cockayne syndrome, there is a high risk of developing this complication.Patient concerns:We report the case of a 44-year-old man, affected by xeroderma pigmentosum, who was admitted to the hospital presenting aspiration pneumoniae caused by worsening dysphagia and with severe hepatotoxicity during the hospitalization.Diagnoses:Acute hepatitis, which was leading to acute liver failure, occurred during antibiotic treatment with metronidazole and ceftazidime with an elevation of liver enzymes consistent with hepatocellular damage pattern.Interventions:Hydration with glucose 5% solution, pantoprazole and vitamin K were administered, meanwhile other causes of hepatitis were ruled out and the ongoing antibiotic treatment was stopped suspecting a drug-induced liver injury.Outcomes:Liver function nearly completely recovered 1 month later with a first rapid improvement, within few days, of aminotransferases and coagulation studies, and slower of cholestatic enzymes.Lessons:We describe the first case available in the literature of hepatotoxicity associated with metronidazole treatment in a xeroderma pigmentosum patient. Clinicians therefore, based on this report and according to the possible underlying mechanism shared by other genetic diseases characterized by alterations in the pathway of DNA-repair, should consider such adverse event also in patients affected by this rare disease. 相似文献
107.
Alessandra Vergori Antonio Boschini Stefania Notari Patrizia Lorenzini Concetta Castilletti Francesca Colavita Giulia Matusali Eleonora Tartaglia Roberta Gagliardini Andrea Boschi Eleonora Cimini Markus Maeurer Pierluca Piselli Leila Angeli Andrea Antinori Chiara Agrati Enrico Girardi 《Viruses》2022,14(7)
The main aim of this study was to describe the clinical and immunological outcomes, as well as the inflammatory profile, of patients with advanced HIV in an assisted-living facility in which an outbreak of SARS-CoV-2 occurred. SARS-CoV-2 humoral and specific T-cell response were analyzed in patients with HIV infection and COVID-19; as a secondary objective of the analysis, levels of the inflammatory markers (IL-1β, IL-6, IL-8, and TNFα) were tested in the HIV/COVID-19 group, in HIV-positive patients without COVID-19, and in HIV-negative patients with mild/moderate COVID-19. Antibody kinetics and ability to neutralize SARS-CoV-2 were evaluated by ELISA assay, as well as the inflammatory cytokines; SARS-CoV-2 specific T-cell response was quantified by ELISpot assay. Mann–Whitney or Kruskal–Wallis tests were used for comparisons. Thirty patients were included with the following demographics: age, 57 years old (IQR, 53–62); 76% male; median HIV duration of infection, 18 years (15–29); nadir of CD4, 57/mmc (23–100) current CD4 count, 348/mmc (186–565). Furthermore, 83% had at least one comorbidity. The severity of COVID-19 was mild/moderate, and the overall mortality rate was 10% (3/30). Additionally, 90% of patients showed positive antibody titers and neutralizing activity, with a 100% positive SARS-CoV-2 specific T-cell response over time, suggesting the ability to induce an effective specific immunity. Significantly higher levels of IL-6, IL-8, and TNF-α in COVID-19 without HIV vs. HIV/COVID-19 patients (p < 0.05) were observed. HIV infection did not seem to negatively impact COVID-19-related inflammatory state and immunity. Further data are mandatory to evaluate the persistence of these immunity and its ability to expand after exposure and/or vaccination. 相似文献
108.
Domenico Umberto De Rose Flaminia Pugnaloni Monica Calì Sara Ronci Stefano Caoci Chiara Maddaloni Ludovica Martini Alessandra Santisi Andrea Dotta Cinzia Auriti 《Viruses》2022,14(4)
(1) Introduction: There is an increasing literature describing neonates born to mothers with SARS-CoV-2 infection (MIS-N) and infants infected with SARS-CoV-2 who presented with a severe disease (MIS-C). (2) Methods: To investigate clinical features of multisystem inflammatory syndrome in neonates and infants under six months of age, we used a systematic search to retrieve all relevant publications in the field. We screened in PubMed, EMBASE and Scopus for data published until 10 October 2021. (3) Results: Forty-eight articles were considered, including 29 case reports, six case series and 13 cohort studies. Regarding clinical features, only 18.2% of MIS-N neonates presented with fever; differently from older children with MIS-C, in which gastrointestinal symptoms were the most common manifestation, we displayed that cardiovascular dysfunction and respiratory distress are the prevalent findings both in neonates with MIS-N and in neonates/infants with MIS-C. (4) Conclusions: We suggest that all infants with suspected inflammatory disease should undergo echocardiography, due to the possibility of myocardial dysfunction and damage to the coronary arteries observed both in neonates with MIS-N and in neonates/infants with MIS-C. Moreover, we also summarize how they were treated and provide a therapeutic algorithm to suggest best management of these fragile infants. 相似文献
109.
110.
Chiara Delli Poggi Maria Fusaro Maria Cristina Mereu Maria Luisa Brandi Luisella Cianferotti 《Nutrients》2022,14(12)
Both osteoporosis with related fragility fractures and cardiovascular diseases are rapidly outspreading worldwide. Since they are often coexistent in elderly patients and may be related to possible common pathogenetic mechanisms, the possible reciprocal effects of drugs employed to treat these diseases have to be considered in clinical practice. Bisphosphonates, the agents most largely employed to decrease bone fragility, have been shown to be overall safe with respect to cardiovascular diseases and even capable of reducing cardiovascular morbidity in some settings, as mainly shown by real life studies. No randomized controlled trials with cardiovascular outcomes as primary endpoints are available. While contradictory results have emerged about a possible BSP-mediated reduction of overall mortality, it is undeniable that these drugs can be employed safely in patients with high fracture risk, since no increased mortality has ever been demonstrated. Although partial reassurance has emerged from meta-analysis assessing the risk of cardiac arrhythmias during bisphosphonates treatment, caution is warranted in administering this class of drugs to patients at risk for atrial fibrillation, possibly preferring other antiresorptives or anabolics, according to osteoporosis guidelines. This paper focuses on the complex relationship between bisphosphonates use and cardiovascular disease and possible co-management issues. 相似文献